Skip to main content
. Author manuscript; available in PMC: 2015 Apr 20.
Published in final edited form as: Neurotherapeutics. 2009 Apr;6(2):372–380. doi: 10.1016/j.nurt.2009.01.001

Figure 3.

Figure 3

Bioavailability of NAX 5055 following several routes of systemic administration. NAX 5055 was administered intravenously (i.v.), intraperitoneally (i.p.), subcutaneously (s.c.) and orally (p.o.) in CF-1 mice. Dose-response data were generated at the following time-points for each route of administration 1 h (i.v., i.p., s.c.) and 2 hr (p.o.).